The vicious cycle of protein clumping in Alzheimer's disease and normal aging
Science Daily
To date, approaches to treatments for Alzheimer's disease have not addressed the contribution of protein insolubility as a general..
Neurodegenerative disease
News and Video Search Results
News coverage
-
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
GlobeNewswire
-
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
GlobeNewswire
-
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
GlobeNewswire
-
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
GlobeNewswire
- More about:
Contactin 4
0 shares
1 views
You might like
Neurodegenerative disease media coverage
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
GlobeNewswire
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to..
-
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
GlobeNewswire
-
Research Sheds Light On How Proteins Linked To Alzheimer’s Disease Influence Neuronal Growth
Eurasia Review
-
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
-
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
GlobeNewswire
Advertisement
More coverage
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
GlobeNewswire
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF
CAMBRIDGE, Mass. and ROSTOCK, Germany, and..
-
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
-
Drug compounds to combat neurodegenerative diseases
Science Daily
-
RNAi Therapeutics Market Size Expected to Reach USD 4.28 Bn by 2033
GlobeNewswire
-
Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients
PR Newswire Asia